Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer-Reference-Cited by-同舟云学术

Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer

Published:1996-10 Issue:8 Volume:7 Page:861-863
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lissoni A.,Zanetta G.,Losa G.,Gabriele A.,Parma G.,Mangioni C.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/7/8/861/474769/7-8-861.pdf

Reference12 articles.

1. Systemic treatment of advanced and recurrent endometrial carcinoma: Current status and future directions;Moore;J Clin Oncol,1991

2. Chemotherapy of metastatic endometrial cancer;Muss;Semin Oncol,1994

3. Phase III trial of doxorubicin +/ - cisplatin in advanced or recurrent endometrial carcinoma; a gynecologic oncology group (GOG) study;Thigpen;Proc Am Soc Clin Oncol,1993

4. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma;Turbow;Cancer Treat Rep,1985

Cited by 84 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy inCTNNB1-mutated endometrial cancer;2023-04-06

2. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer;Gynecologic Oncology;2022-12

3. Endometrial Cancer;Holland‐Frei Cancer Medicine;2022-10-21

4. Interdisciplinary approach to the management of patients with uterine cancer progression;Tumors of female reproductive system;2022-05-08

5. Malignant diseases of the uterus;Comprehensive Gynecology;2022